<DOC>
	<DOCNO>NCT00532792</DOCNO>
	<brief_summary>This Phase 1/2 , randomize , observer-blind , placebo-controlled clinical trial . A maximum 500 eligible subject 10 group enrol , randomize vaccinate study . Subjects receive intramuscular injection either influenza A/H5N1 ( low , medium high dose ) placebo Day 0 Day 21 without patch . This study perform two part . In Part 1 , initial safety evaluation perform 100 randomized subject . A Safety Review Committee ( SRC ) review safety data , include laboratory value , Day 7 visit , compare data Stopping Criteria . If treatment consider safe , Part 2 study initiate second vaccination administer subject Part 1 Day 21 . In Part 2 , remain 400 subject randomize , treat , follow visit structure protocol-defined requirement subject Part 1 , without additional laboratory safety measurement . An SRC review also perform safety data Day 28 visit subject participate Part 1 .</brief_summary>
	<brief_title>A/H5N1 Dose Ranging Study With Adjuvant Patch</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Healthy adult male females 1849 year age ( inclusive ) Signed Informed Consent Women postmenopausal surgically sterile must negative serum urine pregnancy test screening within 24 hour vaccination understanding ( Informed Consent process ) become pregnant employ effective form birth control duration study . Acceptable form birth control : abstinence , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , doublebarrier contraceptive ( condom diaphragm , spermicide ) , IUD Laboratory abnormality [ determine Toxicity Grading Scale ( grade 1 4 ) ] laboratory screen Abnormalities physical examination [ determine Toxicity Grading Scale ( grade 14 ) ] Known allergy component vaccine Known egg protein allergy Known allergy adhesives Known disturbance coagulation Participated research involve investigational product within 45 day plan date first vaccination Donated receive blood blood product plasma within past 45 day Received licensed vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior plan date first vaccination Ever receive investigational enterotoxigenic E. coli , LT , LT ( R192G ) NasalFlu , Berna Biotech , Ltd Ever receive cholera toxin vaccine ( e.g . Orochol™ , Dukoral™ ) History traveler ' diarrhea last two year History abdominal surgery ( exclude Csection , hysterectomy , cosmetic surgery , liposuction , appendectomy , cholecystectomy , ventral hernia repair , surgery pertain gastrointestinal problem ) history , recent acute gastrointestinal illness Previous vaccination pandemic candidate vaccine previous prove contact A/H5N1 wild type virus ( contact individual laboratoryconfirmed A/H5N1 infection contact animal die result A/H5N1 infection ) Recent regular use oral , topical inject steroid medication within 45 day prior first vaccination Use immunosuppressive systemic steroid medication include inhaled steroid within three month prior first vaccination Comorbid condition treatment immunosuppressive , include cancer , diabetes , endstage renal disease , determine Investigator Positive serology HIV1 , HIV2 , HBsAg , HCV History severe atopy Medical history acute chronic skin disease vaccination area ( ) Active skin allergy Signs acute skin infection , sunburn skin abnormality vaccination area ( ) include fungal infection , severe acne , active contact dermatitis , history keloid formation Hirsute ( significant amount hair ) vaccination area ( ) Artificial tanning ( UV radiation ) duration study include screen period Visible tattoo mark ( tattoos/scars ) vaccination area ( ) would prevent appropriate dermatologic monitoring vaccination site ( ) Fever great equal 38.0°C ( 100.4°F ) time plan vaccination Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse Women pregnant breastfeed Acute illness screen baseline Ever serious reaction prior influenza vaccination Developed neurological disorder ( Guillain Barré syndrome ) six week follow previous influenza vaccination Medical history achlorhydria Employee investigational site History employment bird poultry industry considerable exposure bird ( e.g . poultry bird veterinarian , bird breeder , poultry butcher and/or cullers , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Avian</keyword>
	<keyword>Pandemic</keyword>
	<keyword>Influenza</keyword>
	<keyword>A/H5N1</keyword>
</DOC>